A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Immunogenicity of a Single Dose of MW14 Injection in Healthy Subjects
Latest Information Update: 16 Jun 2022
At a glance
- Drugs 9MW 1411 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; First in man
- Sponsors Mabwell (Shanghai) Bioscience
- 14 Jun 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 05 May 2021 Status changed from not yet recruiting to recruiting.